Organon & Co. (NYSE:OGN) Shares Acquired by Barclays PLC

Barclays PLC increased its position in Organon & Co. (NYSE:OGN - Free Report) by 238.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 119,483 shares of the company's stock after purchasing an additional 84,136 shares during the period. Barclays PLC's holdings in Organon & Co. were worth $2,285,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Prospera Private Wealth LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at about $25,000. William B. Walkup & Associates Inc. purchased a new stake in shares of Organon & Co. during the 2nd quarter worth $31,000. Abich Financial Wealth Management LLC grew its stake in shares of Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company's stock worth $45,000 after purchasing an additional 2,315 shares during the period. Atlas Capital Advisors LLC increased its holdings in shares of Organon & Co. by 2,236.5% in the 2nd quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company's stock valued at $46,000 after purchasing an additional 2,147 shares in the last quarter. Finally, Trust Co. of Vermont increased its holdings in shares of Organon & Co. by 109.4% in the 3rd quarter. Trust Co. of Vermont now owns 2,626 shares of the company's stock valued at $50,000 after purchasing an additional 1,372 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on OGN. Evercore ISI upgraded Organon & Co. to a "strong-buy" rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a "neutral" rating to an "underweight" rating and lifted their target price for the stock from $18.00 to $20.00 in a research report on Friday, September 6th.

Organon & Co. Trading Up 1.5 %

Shares of NYSE:OGN traded up $0.22 during trading on Thursday, reaching $14.95. 2,198,296 shares of the stock were exchanged, compared to its average volume of 2,446,618. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of 2.97, a price-to-earnings-growth ratio of 0.81 and a beta of 0.75. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 12-month low of $13.65 and a 12-month high of $23.10. The firm's 50-day moving average price is $15.86 and its 200 day moving average price is $18.80.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.'s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.78 EPS. On average, sell-side analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were issued a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 7.49%. Organon & Co.'s dividend payout ratio is presently 22.22%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.